Clinical Study

Thickness of Extraocular Muscle and Orbital Fat in MRI Predicts Response to Glucocorticoid Therapy in Graves’ Ophthalmopathy

Table 1

Clinical features of each group.

Responsive ()Unresponsive ()Control () value

Age (years)42.83 ± 12.2844.33 ± 10.7945.70 ± 13.660.83
Female (n, %)11 (61.1%)8 (53.3%)6 (60.0%)0.95
Smoking history4 (22.2%)3 (20%)2 (20%)0.99
Alcohol intake2 (11.1%)1 (6.7%)1 (10%)0.91
BMI22.75 ± 2.1124.57 ± 3.8822.01 ± 1.270.06
SBP (mmHg)133.11 ± 17.10131.40 ± 17.15132.30 ± 15.790.96
DBP (mmHg)77.56 ± 10.2283.40 ± 9.4680.70 ± 10.760.26
ALT (U/L)15.67 ± 7.7420.56 ± 14.4118.20 ± 5.160.40
AST (U/L)20.39 ± 7.9521.25 ± 8.0321.90 ± 6.150.88
BUN (mmol/L)4.70 ± 1.493.95 ± 0.964.53 ± 1.120.22
Cr (μmol/L)55.89 ± 22.7844.27 ± 15.4656.30 ± 5.890.13
TG (mmol/L)1.39 ± 0.701.50 ± 0.741.75 ± 0.690.48
TC (mmol/L)4.85 ± 1.195.15 ± 1.494.69 ± 1.330.72
HDL (mmol/L)1.24 ± 0.471.20 ± 0.371.10 ± 0.280.70
LDL (mmol/L)2.86 ± 0.693.23 ± 1.112.81 ± 1.000.52
FT3 (pg/mL)5.75 ± 6.314.23 ± 1.772.99 ± 0.390.25
FT4 (ng/dL)1.62 ± 1.171.43 ± 0.541.15 ± 0.160.36
TSH (mUI/L)0.468 (0.004–2.465)0.070 (0.004–1.15)2.330 (1.304–3.05)0.02
TRAb (UI/L)12.75 (5.78–27.20)12.75 (5.59–22.09)0.580 (0.320–0.650)<0.001
Hyperthyroidism duration (months)14 (7.25–25.5)22 (12–42)0.49
GO duration (months)8.0 (3–12.25)9.5 (4.0–12.5)0.66
Antithyroid treatments
Antithyroid drug6 (33.3%)7 (46.7%)0.44
Radioiodine9 (50.0%)6 (40.0%)0.57
Thyroidectomy3 (16.7%)2 (13.3%)0.79
CAS4.56 ± 1.104.27 ± 1.030.45
Lid width (mm)11.06 ± 1.1210.67 ± 1.028.50 ± 0.86<0.001
Visual acuity0.80 ± 0.150.83 ± 0.180.99 ± 0.170.02
Diplopia0.02
Absent6 (33.3%)4 (26.7%)10 (100%)
Intermittent5 (27.8%)5 (33.3%)0
Inconstant4 (22.2%)4 (26.7%)0
Constant3 (16.7%)2 (13.3%)0

; . TSH: responsive group versus unresponsive group, . TRAb: responsive group versus unresponsive group, . Lid width: responsive group versus unresponsive group, . Visual acuity: responsive group versus unresponsive group, . Diplopia: responsive group versus unresponsive group, .